Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer

Recruiting now · Not applicable

Conditions studied: Breast Cancer

In brief

This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients with localized hormone-dependent breast cancer. 200 patients will be included in the study. Each patient will be followed for one day.

Key facts

Study ID

NCT04740697

Run by

Institut Claudius Regaud

People needed

200

Starts

2021-02-12

Expected to finish

2028-02-01

Last updated by the study team

2026-04-20

Who can join

Age: 2 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years at entry into the study.
• Patient treated for hormone-dependent localized breast cancer requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
• Patients treated with tamoxifen for a maximum of 1 to 3 years.
• Patient affiliated with a Social Security system in France.
• Patients who signed informed consent prior to inclusion in the study and prior to any specific study procedures.

You may not qualify if…

• Pregnant or breastfeeding women.
• Any psychological, family, geographical or sociological condition that does not allow the medical follow-up and/or the procedures foreseen in the study protocol to be respected.
• Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Where it is running

• Institut Universitaire du Cancer de Toulouse - Oncopole — Toulouse, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.